Chronic Iron Overload Clinical Trial
Official title:
Survey to Assess Physicians' Knowledge of Exjade Posology and Biological Monitoring Recommendations as Described in the Educational Materials
Verified date | May 2024 |
Source | Novartis |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The objective of this survey is to assess the knowledge of HCPs in relation to the recommended posology and biological monitoring for Exjade, based on the current locally valid Exjade educational materials (including the physician's reference checklist)
Status | Completed |
Enrollment | 400 |
Est. completion date | February 15, 2024 |
Est. primary completion date | February 15, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Physicians will be required to meet all of the following inclusion criteria: - Must provide consent for participation - Must spend =50% of time in direct patient care - Have treated patients with transfusional iron overload or non-transfusion-dependent thalassemia with chelation therapy during the last 12 months. - Have prescribed Exjade and/or generic deferasirox within the last 12 months. Exclusion Criteria: Physicians meeting the following criterion will not be eligible to take the survey: • Currently employed by a pharmaceutical company, health care company, market research company, advertising agency, or government agency involved in pharmaceutical research or marketing. |
Country | Name | City | State |
---|---|---|---|
Switzerland | Novartis Investigative Site | Basel |
Lead Sponsor | Collaborator |
---|---|
Novartis Pharmaceuticals |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean percentage of correct responses related to knowledge of posology and biological monitoring recommendations as described in the Exjade EU Summary of Product Characteristics (SmPC) | The primary endpoint is a composite endpoint based on the percentages of HCPs with correct responses to all questions included in the composite regarding the below information:
Administration and dosing of Exjade (deferasirox) FCT Biological monitoring |
Through study completion, an average of 6 months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05440487 -
Study to Assess Iron Chelation Therapy in Patients With Chronic Iron Overload
|
||
Completed |
NCT01825512 -
Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients
|
Phase 3 | |
Completed |
NCT01740713 -
Pharmacokinetic Study of Deferiprone in Paediatric Patients
|
Phase 2 | |
Completed |
NCT02720536 -
Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation
|
Phase 3 |